The evolving role of familial history for prostate cancer

Acta Oncologica

Volumn 50, Issue 1, 2011, Pages 14-24

  Colloca, Giuseppe ^a   Venturino, Antonella ^a  

^a ASL 1 Imperiese   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BRCA2 PROTEIN; CYTOCHROME P450 17; ESTROGEN; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE 2; VITAMIN D RECEPTOR;

ANDROGEN METABOLISM; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SUSCEPTIBILITY; EARLY DIAGNOSIS; FAMILY HISTORY; GENE EXPRESSION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; DATABASES, FACTUAL; GENES, DOMINANT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MEDICAL HISTORY TAKING; PENETRANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 78650537855     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.521191     Document Type: Review

References (95)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-81. (Pubitemid 46359643)
2. Carter B, Bova G, Beaty Y, Steinberg G, Childs B, Isaacs W, et al. Hereditary prostate cancer: Epidemiologic and clinical features. J Urol 1993;150:797-802. (Pubitemid 23241269)
3. Hemminki K, Czene K. Age specfic and attributable risks of familial prostate carcinoma from the Family-Cancer Database. Cancer 2002;95:1346-53. (Pubitemid 35013071)
4. Ahn J, Moslehi R, Weinstein SJ, Snyder K, Virtamo J, Albanes D. Family history of prostate cancer and prostate cancer risk in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Int J Cancer 2008;123:1154-9.
5. Cerhan JR, Parker AS, Putnam SD, Chiu BC, Lynch CF, Cohen MB, et al. Family history and prostate cancer risk in a population-based cohort of Iowa men. Cancer Epidemiol Biomarkers Prev 1999;8:53-60. (Pubitemid 29090870)
6. Kalish LA, Scott McDougal W, McKinlay JB. Family history and the risk of prostate cancer. Urology 2000;56:803-6.
7. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at diagnosis and age at death in familial prostate cancer. Oncologist 2009;14:1209-17.
8. Johns LE, Houlston RS. A systematic review and metaanalysis of familial prostate cancer risk. BJU Int 2003;91: 789-94. (Pubitemid 36724060)
9. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: Systematic review and meta-analysis. Int J Cancer 2003;107:797-803. (Pubitemid 37339734)
10. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci 1992;89:3367-71.
11. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343: 78-85. (Pubitemid 30451850)
12. Page WF, Braun MM, Partin AW, Caporaso N, Walsh P. Heredity and prostate cancer: A study of World War II veteran twins. Prostate 1997;33:240-5. (Pubitemid 27524702)
13. Ahlbom A, Lichtenstein P, Malmstrom H, Feychting M, Hemminki K, Pedersen NL. Cancer in twins: Genetic and nongenetic familial risk factors. J Natl Cancer Inst 1997; 89:287-93. (Pubitemid 27085890)
14. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J Urol 1994; 152:1484-9. (Pubitemid 24326292)
15. Damber L, Gronberg H, Damber JE. Familial prostate cancer and possible associated malignancies: Nation-wide register cohort study in Sweden. Int J Cancer 1998;78:293-7. (Pubitemid 28445363)
16. Schuurman AG, Zeegers MP, Goldbohm RA, van den Brandt PA. A case-cohort study on prostate cancer risk in relation to family history of prostate cancer. Epidemiology 1999; 10:192-5. (Pubitemid 29093960)
17. Hemminki K, Sundquist J, Bermejo JL. How common is familial cancer? Ann Oncol 2008;19:163-7.
18. Verhage BA, Baffoe-Bonnie AB, Baglietto L, Smith DS, Bailey-Wilson JE, Beaty TH, et al. Autosomal dominant inheritance of prostate cancer: A confi rmatory study. Urology 2001;57:97-101. (Pubitemid 32065827)
19. Monroe KR, Yu MC, Kolonel LN, Coetzee GA, Wilkens LR, Ross RK, et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med 1995;1:827-9.
20. MacInnis R, Antoniou AC, Eeles RA, Severi G, Guy M, McGuffog L, et al. Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet Epidemiol 2010;34:42-50.
21. Pakkanen S. Segregation analysis of 1,546 prostate cancer families in Finland shows recessive inheritance. Hum Genet 2007;121:257-67. (Pubitemid 46404459)
22. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease. Hum Mol Genet 2001;10:2313-8. (Pubitemid 32998847)
23. Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey- Wilson JE, Carpten JD, et al. Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics Using Novel sum- LINK and sumLOD analyses. Prostate 2010;70:735-44.
24. Schaid DJ. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004;13:R103-21. (Pubitemid 38443804)
25. Schaid DJ, Chang BL. Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13. Prostate 2005;63:276-90. (Pubitemid 40571062)
26. Witte JS. Multiple prostate cancer risk variants on 8q24. Nat Genet 2007;39:579-80. (Pubitemid 46676095)
27. Haiman CA, Patterson N, Freedman ML, Myers SR, Pike MC, Waliszewska A, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007;39:638-44. (Pubitemid 46676106)
28. Gudmundsson J, Sulem P, Steinthorsdottir V, Bergthorsson JT, Thorleifsson G, Manolescu A, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007;39: 977-83. (Pubitemid 47185170)
29. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci 2006;103:14068-73. (Pubitemid 44452981)
30. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39: 645-9. (Pubitemid 46676108)
31. Eeles RA, Kote-Jarai Z, Giles GG, Olama AAA, Guy M, Jugurnauth SK, et al. Multiple newly identifi ed loci associated with prostate cancer susceptibility. Nat Genet 2008;40: 316-21. (Pubitemid 351311772)
32. Kote-Jarai Z, Easton DF, Stanford JL, Ostrander EA, Schleutker J, Ingles SA, et al. Multiple novel prostate cancer predisposition loci confi rmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 2008;17:2052-61.
33. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbour germline mutations in the BRCA2 gene. Am J Hum Genet 2003;72:1-12. (Pubitemid 36056838)
34. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N, et al. Multiple loci identifi ed in a genome-wide association study of prostate cancer. Nat Genet 2008;40:310-5. (Pubitemid 351311773)
35. Gudmundsson J, Sulem P, Rafnar T, Bergthorsson JT, Manolescu A, Gudbjartsson D, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008;40:281-3. (Pubitemid 351311771)
36. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, et al. Prostate cancer susceptibility genes: Lessons learned and challenges posed. Endocrine-Related Cancer 2003;10:225-59. (Pubitemid 36763535)
37. Van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Onc Hematol 2007;61:104-39. (Pubitemid 46073780)
38. L indstrom S, Wiklund F, Adami H-O, Augustsson Balter K, Adolfsson J, Gronberg H. Germ-line genetic variation in the key androgen-regulating genes Androgen Receptor, Cytochrome P450, and Steroid-5-alpha-Reductase type 2 is important for prostate cancer development. Cancer Res 2006; 66:11077-83. (Pubitemid 44877009)
39. Chen C, Weiss NS, Stanczyk FZ, Lewis SK, DiTommaso D, Etzioni R, et al. Endogenous sex hormones and prostate cancer risk: A case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 2003;12:1410-6. (Pubitemid 38031742)
40. Shaneyfelt T, Husein R, Bubley G, Mantzoros C. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847-53. (Pubitemid 30106616)
41. Perry AS, Foley R, Woodson K, Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocrine-Related Cancer 2006;13:357-77. (Pubitemid 43886663)
42. Ph è V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1364-70.
43. Dianat SS, Margreiter M, Eckersberger E, Finkelstein J, Kuehas F, Herwig R, et al. Gene polymorphisms and prostate cancer: The evidence. BJU Int 2009;104:1560-72.
44. Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL. Glutathione S-Transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006;66:146-56. (Pubitemid 43191236)
45. Brand TC, Bermejo C, Canby-Hagino E, Troyer DA, Baillargeon J, Thompson IM, et al. Association of polymorphisms in TGFB1 and prostate cancer prognosis. J Urol 2007;179:754-8.
46. Cussenot O, Azzouzi AR, Nicolaiew N, Fromont G, Mangin P, Cormier L, et al. Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: The hidden face of estrogens. J Clin Oncol 2007; 25:3596-602. (Pubitemid 47376605)
47. Mononen N, Seppala EH, Duggal P, Autio V, Ikonen T, Ellonen P, et al. Profi ling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Cancer Res 2006;66:743-7. (Pubitemid 43165937)
48. Nock NL, Cicek MS, Li L, Liu X, Rybicki BA, Moreira A, et al. Polymorphisms in estrogen bioactivation, detoxifi cation and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis 2006;27:1842-8. (Pubitemid 44288666)
49. Loeb S, Helfand BT, Kan D, Isaacs WB, Catalona WJ. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness? BJU Int 2009; 104:1200-3.
50. Ritchey JD, Huang W-Y, Chokkalingam AP, Gao Y-T, Deng J, Levine P, et al. Genetic variants of DNA repair genes and prostate cancer: A population-based study. Cancer Epidemiol Biomarkers Prev 2005;14:1703-9. (Pubitemid 40995083)
51. Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res 2003;63:8542-8. (Pubitemid 37549514)
52. Rohrmann S, Roberts WW, Walsh PC, Platz EA. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate 2003;55:140-6. (Pubitemid 36444001)
53. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, et al. Obesity is negatively associated with prostate-specific antigen in U.S. Men, 2001-2004. Cancer Epidemiol Biomarkers Prev 2007;16:70-6. (Pubitemid 46174266)
54. Norrish AE, McRae CU, Cohen RJ, Jackson RT. A population- based study of clinical and pathological prognostic characteristics of men with familial and sporadic prostate cancer. BJU Int 1999;84:311-5.
55. Fromont G, Yacoub M, Valeri A, Mangin P, Vallacien G, Cancel-Tassin G, et al. Differential expression of genes related to androgen and estrogen metabolism in hereditary versus sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2008;17:1505-9.
56. Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun MJ, et al. Family history and risk of fatal prostate cancer. Epidemiology 1997;8:653-7. (Pubitemid 27449497)
57. Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: An independent predictor of treatment outcome. J Clin Oncol 1997;15:1478-80. (Pubitemid 27167383)
58. Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology 2003;61:1193-7. (Pubitemid 36694001)
59. Gronberg H, Damber L, Tavelin B, Damber JE. No difference in survival between sporadic, familial and hereditary prostate cancer. Br J Urol 1998;82:564-7. (Pubitemid 28477301)
60. Hanlon AL, Hanks GE. Patterns of inheritance and outcome in patients treated with external beam radiation for prostate cancer. Urology 1998;52:735-8. (Pubitemid 28489690)
61. Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, et al. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate 2000;45:66-71.
62. Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. Aggressiveness of familial prostate cancer. J Clin Oncol 2006;24:3445-50. (Pubitemid 46638902)
63. Roehl KA, Loeb S, Antenor JAV, Corbin N, Catalona WJ. Characteristics of patients with familial versus sporadic prostate cancer. J Urol 2006;176:2438-42. (Pubitemid 44755061)
64. Roupret M, Fromont G, Bitker M, Gattegno B, Vallancien G, Cussenot O. Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology 2006;67:1028-32. (Pubitemid 43964822)
65. Siddiqui SA, Sengupta S, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Impact of familial and hereditary prostate cancer on cancer specific survival after radical retropubic prostatectomy. J Urol 2005;176:1118-21. (Pubitemid 44142572)
66. Peters CA, Stock RG, Blacksburg SR, Stone NN. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2009;73:24-9.
67. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41. (Pubitemid 351830300)
68. Alers JC, Krijtenburg P-J, Vis AN, Hoedemaeker RF, Wildhagen MF, Hop WCJ, et al. Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies. Am J Pathol 2001;158:399-406.
69. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profi ling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci 2004;101:811-6. (Pubitemid 38121040)
70. Nelson PS. Predicting prostate cancer behavior using transcript profiles. J Urol 2004;172:S28-S33.
71. True L, Coleman I, Hawley S, Huang C-Y, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci 2006;103:10991-6. (Pubitemid 44148406)
72. Witte JS, Goddard KAB, Conti DV, Elston RC, Lin J, Suarez BK, et al. Genomwide scan for prostate canceraggressiveness loci. Am J Hum Genet 2000;67:92-9. (Pubitemid 30481547)
73. Rebbeck TR. Inherited genotype and prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev 2002;11:945-52. (Pubitemid 35192642)
74. R oss RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, et al. Inherited variation in the androgen pathway is associated with the Efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Onc 2008; 26:842-7. (Pubitemid 351398074)
75. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in Caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008;14:3312-8.
76. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang Q-X, Olsson H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 1999;81:672-6. (Pubitemid 29458864)
77. Sharifi N, Dahut WL, Figg WD. The genetics of castrationresistant prostate cancer: What can the germline tell us? Clin Cancer Res 2008;14:4691-3.
78. Yoon PW, Scheuner MT, Peterson-Oehlke KL, Gwinn M, Faucett A, Khoury MJ. Can family history be used as a tool for public health and preventive medicine? Genet Med 2002;4:304-10. (Pubitemid 44698565)
79. Toms JR. Cancer Stats monograph 2004. Cancer Research UK, 2004.
80. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;148:435-48.
81. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level≤ 4.o ng per milliliter. N Engl J Med 2004;350:2239-46.
82. Canby-Hagino E, Hernandez J, Brand TC, Troyer DA, Higgins B, Ankerst DP, et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology 2007;70: 748-52. (Pubitemid 350030239)
83. Parekh DJ, Ankerst DP, Higgins BA, Hernandez J, Canby- Hagino E, Brand T, et al. External validation of the prostate cancer prevention trial risk calculator in a screened population. Urology 2006;68:1152-5. (Pubitemid 44880388)
84. Nam RK, Zhang WW, Trachtenberg J, Seth A, Klotz LH, Stanimirovic A, et al. Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res 2009;15:1787-93.
85. Loeb S, Carter HB, Walsh PC, Isaacs WB, Kettermann A, Tanaka T, et al. Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. J Urol 2009;182:101-5.
86. Gallus S, Foschi R, Talamini R, Altieri A, Negri E, Franceschi S, et al. Risk factors for prostate cancer in men aged less than 60 years: A case-control study from Italy. Urology 2007;70: 1121-6. (Pubitemid 350297359)
87. Drake BF, Lathan CS, Okechukwu CA, Bennett GG. Racial differences in prostate cancer screening by family history. Ann Epidemiol 2008;18:579-83.
88. Andersson SO, Baron J, Wolk A, Lindgren C, Bergstrom R, Adami HO. Early life risk factors for prostate cancer: A population-based case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 1995;4:187-92.
89. Hemminki K, Rawal R, Bermejo JL. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. Int J Cancer 2005;113:312-5. (Pubitemid 39628324)
90. Bratt O, Gamo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst 2010;102:1-8.
91. Orom H, Kiviniemi MT, Underwood-III W, Ross L, Shavers VL. Perceived cancer risk: Why is it lower among nonwhites than whites? Cancer Epidemiol Biomarkers Prev 2010;19: 746-54.
92. Wallner LP, Sarma AV, Lieber MM, St.Sauver JL, Jacobson DJ, McGree ME, et al. Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: The Olmsted County Study. Cancer Epidemiol Biomarkers Prev 2008;17: 3588-92.
93. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, et al. Estrogen-dependent signalling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100:815-25. (Pubitemid 351809667)
94. Bastian PJ, Palapattu GS, Yegnasubramanian S, Rogers CG, Lin X, Mangold LA, et al. CpG Island Hypermethylation profi le in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol 2007;179:529-35.
95. Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocrine-Related Cancer 2008;15: 11-25. (Pubitemid 351449724)